Literature DB >> 9686771

Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine.

M Gassen1, A Gross, M B Youdim.   

Abstract

A significant body of evidence has been provided to support the hypothesis that oxidant stress may be responsible for the degeneration of dopaminergic neurons in the substantia nigra pars compacta in Parkinson's disease. Apomorphine, a dopamine D1/D2-receptor agonist in the clinical therapy of Parkinson's disease, has been found to be a potent antioxidant and to prevent free radical reaction in rat brain mitochondrial fraction. In this article we show that 1-10 microM of apomorphine protects rat pheochromocytoma (PC12) cells from the toxic effects of H2O2 (0.6 mM) and the neurotoxin 6-hydroxydopamine (150 microM). Neither of these effects were exhibited by ascorbic acid, desferal, lisuride, or bromocriptine. Although pergolide exhibited some protection of PC12 cells against H2O2 toxicity, it was not as potent as apomorphine. In light of the present findings and the clinical reports that parkinsonian patients on long-term apomorphine therapy stabilize clinically and can be weaned off L-dopa, one may assume that apomorphine can exert a neuroprotective activity by way of its potent antioxidant properties.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9686771     DOI: 10.1002/mds.870130409

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  7 in total

1.  Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines.

Authors:  Venugopalan D Nair; C Warren Olanow; Stuart C Sealfon
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

2.  Apomorphine and Alzheimer Aβ: roles for regulated α cleavage, autophagy, and antioxidation?

Authors:  John W Steele; Sam Gandy
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

Review 3.  Role of apomorphine in the treatment of Parkinson's disease.

Authors:  Allison Boyle; William Ondo
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

Review 4.  Dopaminergic agonists: possible neurorescue drugs endowed with independent and synergistic multisites of action.

Authors:  Daniela Uberti; Irene Bianchi; Luca Olivari; Giulia Ferrari-Toninelli; Sara A Bonini; Maurizio Memo
Journal:  Neurochem Res       Date:  2007-05-08       Impact factor: 3.996

5.  A sporadic Parkinson disease model via silencing of the ubiquitin-proteasome/E3 ligase component SKP1A.

Authors:  Tali Fishman-Jacob; Lydia Reznichenko; Moussa B H Youdim; Silvia A Mandel
Journal:  J Biol Chem       Date:  2009-09-11       Impact factor: 5.157

6.  Neuroprotective effects of chalcones from Myracrodruon urundeuva on 6-hydroxydopamine-induced cytotoxicity in rat mesencephalic cells.

Authors:  Hélio V Nobre-Júnior; Ricardo A Oliveira; Flavio D Maia; Marcelle A S Nogueira; Manoel Odorico de Moraes; Mary Anne M Bandeira; Geanne M Andrade; Glauce S B Viana
Journal:  Neurochem Res       Date:  2008-11-13       Impact factor: 3.996

Review 7.  Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.